The STING Signaling Pathway in Prostate Cancer: Mechanisms, Influencing Factors, and Therapeutic Strategies

View at publisher Summarise with VIRAT
Authors: Na Qu, Meng Zhang, Yating Ji, Mingxia Liu, Mengjiao Liu, L. J. Chen
Cited by: 0
References: 107

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Prostate cancer (PCa) is a common malignancy in men globally. The cGAS-STING pathway shows promise in its treatment as it can enhance anti-tumor immunity and promote immunogenic cell death. However, the tumor microenvironment, with factors like immunosuppressive cells and gene regulatory factors, limits the efficacy of STING pathway activation. OBJECTIVE: This review aims to systematically summarize the recent progress in targeting the cGAS-STING pathway for the treatment of prostate cancer. METHODS: We first introduce the core mechanisms of STING signaling, and then explore its specific role in the pathogenesis and progression of prostate cancer. We analyze the key factors in the TME that limit STING activation, such as immunosuppressive cells and epigenetic regulators. In addition, we summarize the current strategies targeting STING, including STING agonists, combination therapies with immune checkpoint inhibitors, and radiotherapy-based approaches. CONCLUSION: Our analysis concludes that targeting the cGAS-STING pathway holds significant potential to overcome therapy resistance and improve outcomes in prostate cancer, although further research is needed to optimize its clinical application.

Fields of Study & Subjects

interferon and immune responses Cancer Immunotherapy and Biomarkers Prostate Cancer Treatment and Research

Publication details

Journal / source
Immunological Investigations
Volume
55
Issue
4
Pages
803–832
Publication date
27 March 2026
Language
EN